

PATIENT INFORMATION				
Patient Name: _____		Patient SSN#: _____		
Address: _____		Address, City, State, Zip Code		
Phone #: _____	2 nd Phone #: _____	Date of Birth: _____	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Weight (lbs): _____		Height (in.): _____ Allergies: _____		
Primary Insurance: _____		Secondary Insurance: _____		
ID#: _____	Phone #: _____	ID#: _____	Phone #: _____	
FAX COPY OF INSURANCE CARD (FRONT & BACK)				
CLINICAL INFORMATION				
ICD-10 Diagnosis <input type="checkbox"/> M80.0 Age-related osteoporosis w/fracture <input type="checkbox"/> M80.8 Other osteoporosis w/fracture <input type="checkbox"/> M81.0 Age-related osteoporosis w/o fracture <input type="checkbox"/> M81.6 Localized Osteoporosis <input type="checkbox"/> M81.8 Other Osteoporosis w/o fracture <input type="checkbox"/> M85.9 Bone density and structure disorders <input type="checkbox"/> M88.0 Paget's Disease <input type="checkbox"/> M89.9 Disorder of bone, unspecified		Calcium Levels: _____ Date: _____ Time: _____ SrCr: _____ Date: _____ Time: _____ BMD/T-Scores: _____ Location: _____ Date: _____ Is therapy new for patient? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient high risk? <input type="checkbox"/> Yes <input type="checkbox"/> No Osteoporotic fracture? <input type="checkbox"/> Yes- Date: _____ Location: _____ <input type="checkbox"/> No		
FAX COPY OF ORTHOPEDIC SCANS AND ALL RELATED CLINICAL/LAB INFO				
Prior Treatment/Therapy (If Any)		Reason for Discontinuation		Start and End Date of Therapy
_____		_____		_____
_____		_____		_____
MEDICAL RECONCILIATION				
1. _____		3. _____		5. _____
2. _____		4. _____		6. _____
MEDICATION	STRENGTH	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> BONIVA®	<input type="checkbox"/> 3 mg/3 mL	Inject the contents of 1 PFS intravenously every 3 months. To be administered by a healthcare professional.	<input type="checkbox"/> 1 PFS	
<input type="checkbox"/> FORTEO®	<input type="checkbox"/> 600 mcg/2.4 mL	Inject 20 mcg subcutaneously once daily. Discard device 28 days after first use. Dispensed with BD Mini™ Pen Needles.	<input type="checkbox"/> 1 Pen	
<input type="checkbox"/> PROLIA®	<input type="checkbox"/> 60 mg/1 mL	Inject contents of 1 PFS subcutaneously every 6 months.	<input type="checkbox"/> 1 PFS	
<input type="checkbox"/> RECLAST®	<input type="checkbox"/> 5 mg/100 mL	Infuse 5 mg intravenously over no less than 15 minutes once annually.* (Ready to infuse solution) *Administer in MD Office	<input type="checkbox"/> 1 Vial	
<input type="checkbox"/> TYMLOS™	<input type="checkbox"/> 3120 mcg/1.56 mL	Inject 80 mcg subcutaneously once daily.	<input type="checkbox"/> 1 box	
<input type="checkbox"/> PEN NEEDLES	<input type="checkbox"/> 31 gauge <input type="checkbox"/> 32 gauge	<input type="checkbox"/> 4 mm <input type="checkbox"/> 6 mm <input type="checkbox"/> 5 mm <input type="checkbox"/> 8 mm	100	4
Injection Training Provided By: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Delta Drugs Ship to: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Home <input type="checkbox"/> Other: _____				
PHYSICIAN INFORMATION				
Physician Name: _____		Contact: _____		NPI#: _____
Address: _____		Address, City, State, Zip Code		
Phone #: _____		Fax#: _____		Email: _____
Physician's Signature: _____		Date: _____		<input type="checkbox"/> Dispense As Written
I AUTHORIZE DELTA DRUGS AND ITS REPRESENTATIVES TO ACT AS AN AGENT TO INITIATE AND EXECUTE THE INSURANCE PRIOR AUTHORIZATION PROCESS.				